OverviewChartNewsTraderScreen

Morgan Stanley Call 225 COR 20.09.../  DE000ME1QD32  /

Stuttgart
2024-05-17  6:53:18 PM Chg.+0.10 Bid8:31:25 PM Ask8:31:25 PM Underlying Strike price Expiration date Option type
8.23EUR +1.23% 8.27
Bid Size: 2,500		 8.35
Ask Size: 2,500		 Cencora Inc 225.00 USD 2024-09-20 Call
GlobeNewswire 05-15 Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Cor...
GlobeNewswire 05-13 Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5...
GlobeNewswire 05-09 Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 202...
GlobeNewswire 05-02 Outlook Therapeutics® to Present at the Retina World Congress 2024
GlobeNewswire 04-29 Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Show...
GlobeNewswire 04-17 2024 ICCC Program Provides Free Training, Education, and Mentorship to Small Business Owners
GlobeNewswire 04-15 Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
GlobeNewswire 03-22 Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for ...
GlobeNewswire 03-18 Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
GlobeNewswire 03-18 Parexel Announces CEO Succession Plan
GlobeNewswire 03-12 Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split
GlobeNewswire 02-14 Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corp...
GlobeNewswire 01-23 Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-...
GlobeNewswire 01-02 Coherus Announces U.S. Launch of LOQTORZI™
GlobeNewswire 2023-12-22 Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinica...
GlobeNewswire 2023-12-19 Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ...
GlobeNewswire 2023-12-06 Outlook Therapeutics® Announces Strategic Organizational Realignment
GlobeNewswire 2023-11-27 Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path For...
GlobeNewswire 2023-11-14 Outlook Therapeutics® Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior V...
GlobeNewswire 2023-11-02 Outlook Therapeutics® Provides Update on Type A Meetings with FDA
GlobeNewswire 2023-11-01 Outlook Therapeutics® to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (IN...
Newsfile Corp 2023-10-26 Zenith Epigenetics Ltd. Announces Collaboration with Cencora on ZEN-3694
GlobeNewswire 2023-09-29 Outlook Therapeutics® Requests Type A Meeting With FDA
GlobeNewswire 2023-09-21 Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
TeleTrader 2021-07-21 J&J reaches $5 billion opioid settlement in US